In this article

本文中

NVO

NVO

NVO

新活力组织

LLY

礼来公司

Follow your favorite stocks

关注你喜爱的股票

CREATE FREE ACCOUNT

创建免费账户

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026.

丹麦哥本哈根巴格斯韦尔德诺和诺德公司办公室前展示其标志，2026年2月4日。

Tom Little | Reuters

汤姆·利特尔 | 路透社

The Food and Drug Administration on Thursday approved a higher dose version of

美国食品药品监督管理局周四批准了更高剂量的版本

Novo Nordisk

诺和诺德

's blockbuster weight loss injection Wegovy, as the company pushes to win back market share from chief rival

的重磅减肥注射剂Wegovy，该公司正努力从主要竞争对手手中夺回市场份额

Eli Lilly

礼来公司

.

。

Novo expects to launch the higher, 7.2-milligram dose of Wegovy in April. The Danish drugmaker is positioning that version to better compete with Lilly's obesity drug Zepbound, which has

诺和诺德预计将在四月推出更高剂量的7.2毫克Wegovy。这家丹麦制药商正将该版本定位为更好地与礼来的减肥药Zepbound竞争，后者已

proven to be more effective

被证明更有效

at promoting weight loss than the standard, 2.4-milligram dose of Wegovy.

在促进减肥方面比标准的2.4毫克剂量的Wegovy更有效。

That higher efficacy has helped Zepbound become the preferred obesity medication among prescribers and patients, even though it entered the U.S. market later than Wegovy, and has solidified Lilly's position as the dominant player in the space.

这种更高的疗效帮助Zepbound成为处方医生和患者首选的肥胖症药物，尽管它比Wegovy更晚进入美国市场，并巩固了礼来公司在该领域的主导地位。

The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial. The standard 2.4-milligram dose of Wegovy has shown around 15% weight loss on average in clinical trials.

在三期试验中，高剂量的Wegovy在72周内帮助肥胖患者平均减重20.7%。标准2.4毫克剂量的Wegovy在临床试验中平均显示出约15%的体重减轻。

'I think it really makes it more competitive, and it really reduces the delta there,' Dr. Jason Brett, principal U.S. medical head at Novo Nordisk, said in an interview on Thursday ahead of the approval.

“我认为这确实让它更具竞争力，并且确实缩小了那里的差距，”诺和诺德美国首席医学官杰森·布雷特博士在周四批准前的一次采访中表示。

'But even more importantly, I think it just gives patients another option if they're not reaching their targets, and achieving some of these higher weight losses for certain patients,' he added.

“但更重要的是，我认为如果患者没有达到他们的目标，这能给他们提供另一个选择，并且帮助某些患者实现更大的减重效果，”他补充道。

In a separate phase three trial on patients with obesity and Type 2 diabetes, high-dose Wegovy demonstrated an average weight loss of 14.1%. People with diabetes typically have a harder time losing weight than people without the condition.

在另一项针对肥胖症和2型糖尿病患者的第三阶段试验中，高剂量Wegovy显示出平均体重减轻14.1%的效果。糖尿病患者通常比非糖尿病患者更难减肥。

It marks the first approval of a GLP-1 treatment under the

它标志着首个GLP-1治疗药物的获批。

FDA's new national priority voucher plan

FDA的新国家优先券计划

that aims to cut drug review times to one-to-two months for companies the agency says are supporting U.S. national health priorities. The FDA launched the pilot plan in June.

该计划旨在将药物审查时间缩短至一到两个月，适用于那些支持美国国家健康重点项目的公司。FDA于六月启动了该试点计划。

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

将CNBC设置为Google上的首选来源，不错过商业新闻最值得信赖的名字的任何时刻。